OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
Ocugen, Inc. (NASDAQ:OCGN) is one of the High-Flying Penny Stocks to Buy. On March 11, Ocugen, Inc. (NASDAQ:OCGN) was ...
A 2026 company-issued report outlining Retina Clear's 'Red Root Hack' marketing narrative, ingredient research context, ...
Eye imaging may help distinguish ALS from Alzheimer’s disease by revealing differences in retinal protein deposits using polarized light.
Ocugen OCGN is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and ...
His method of locating genes in human DNA allowed researchers to find disease-causing genes, and later to map the entire, ...
Nemours Children's Hospital is now offering Lyfgenia gene therapy. The treatment aims to reduce pain crises and hospital visits for young patients.
The approval and availability of Epioxa, a noninvasive, epithelium-on, oxygen-enriched treatment for keratoconus represents a significant advancement in patient care. Not only does Epioxa provide a ...
Khaleej Times on MSN
How UAE-based geneticist helped identify previously unknown rare genetic disorder
When standard genetic tests came back negative for several children in the UAE with unexplained developmental delays and muscle weakness, doctors could easily have stopped looking. Instead, further ...
Long-term lithium therapy remains the most effective maintenance treatment for bipolar disorder, yet it poses a significant risk of progressive renal impairment in a subset of patients. Early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results